Zion Market Research has published a new report titled “Skeletal Dysplasia Market by Type (X-linked Hypophosphatemia, Hypophosphatasia, Achondroplasia, Fibrodysplasia Ossificans Progressive, Multiple Osteochondromas, and Others), and by Treatment (Medication, Surgery, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”. According to the report, global demand for skeletal dysplasia market was valued at approximately USD 2,493.6 million in 2018, and is expected to generate revenue of around USD 3,303.6 million by end of 2025, growing at a CAGR of around 4.1% between 2019 and 2025.
A varied group which includes more than 450 disorders related to bones is knows as skeletal dysplasia. It consists of large number of disorders development in the bone and cartilage. It has a wide spectrum and any part of the skeleton can be affected by skeletal dysplasia including abnormalities like size, bone shape, short stature, and density. It is caused due to disturbance in the growth of bone during early stages of the fetal development.
Request Free Sample is Available @ https://www.zionmarketresearch.com/sample/skeletal-dysplasia-market
Rising prevalence rate of congenital disorders and birth defects are some of the factors boosting the market growth for skeletal dysplasia. As per stats provided by the Center of Disease Control & Prevention (CDC), 1 in every 33 babies in the U.S. is affected due to birth defects every year. Rising number of genetic disorders is also favoring market growth along with rising R&D activities for drug development is also boosting the market growth for skeletal dysplasia. Moreover, rising consumption of cigarettes and alcohol, and lifestyle changes are also among the major factors boosting the market growth globally.
The market for skeletal dysplasia is segmented based on treatment, type, and regions. Based on type the market is segmented into hypophosphatasia, fibrodysplasia ossificans progressive, achondroplasia, x-linked hypophosphatemia, multiple osteochondromas, and others. The segment for hypophosphatasia (HPP) held major share of the market in 2018. The growth of this segment is attributed to growing prevalence of the disease type. Hypophosphatasia is likely to be 1 per 300,000 births in the Europe alone.
Based on treatment type the market is segmented into medication, surgery, and others. The segment for surgery held major share of the market in terms of revenue in 2018. Growing preference by patients towards surgeries is one of the major factors responsible for this segmental market growth.
The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries. Europe held major share of the market in 2018 owing to growing awareness of this disease and high adoption rate of surgeries being some of the factors responsible for the region’s growth.
Some of the players within global skeletal dysplasia market include BioMarin, Regeneron, Amgen, Inc., Merck KGaA, Alexion Pharmaceuticals, Inc., and Ipsen Group.
This report segments the skeletal dysplasia market as follows:
Global Skeletal Dysplasia Market: Type Segment Analysis
Global Skeletal Dysplasia Market: Treatment Segment Analysis
Global Skeletal Dysplasia Market: Regional Segment Analysis
To view TOC of this report is available upon request @ https://www.zionmarketresearch.com/toc/skeletal-dysplasia-market